Current Edition

Biohaven

Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users

Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie—thanks to Nurtec ODT’s dual acute-plus-prevention nod and an aggressive digital-first strategy. Digital ads across …

Continue Reading →